Patent ID: 6784179
Filing Date: 2004-08-31
Classification: A61P,C07D,Y10S

Abstract:
A method of treating a vascular disease comprising administering to a human or nonhuman body the following:a) an endothelium-derived relaxing factor, an atrial natriuretic factor, a brain natriuretic peptide, a C-type natriuretic peptide, or an endothelium-dependent relaxing agent, and b) a therapeutically effective amount of a compound having a formula of or salts or solvates thereof, in which: R0 represents hydrogen, halogen, or C1-6alkyl; R1 represents hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, C3-8cycloalkyl, C3-8cycloalkylC1-3alkyl, arylC1-3alkyl, wherein aryl is phenyl or phenyl substituted with one to three substituents selected from the group consisting of halogen, C1-6alkyl, C1-4alkoxy, methylenedioxy, and mixtures thereof, or heteroarylC1-3alkyl, wherein heteroaryl is thienyl, furyl or pyridyl, each optionally substituted with one to three substituents selected from the group consisting of halogen, C1-6alkyl, C1-6alkoxy, and mixtures thereof; R2 represents an optionally substituted monocyclic aromatic ring, selected from benzene, thiophene, furan, and pyridine, or an optionally substituted bicyclic ring â€ƒattached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring A is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulfur, and nitrogen; and R3 represents hydrogen or C1-3alkyl, or R1 or R3 together represent a 3- or 4-membered alkyl or alkenyl chain component of a 5- or 6-membered ring.